Comparison

Cagrilintide vs. Survodutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Survodutide

Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Survodutide
Germany	Unapproved	Unapproved
DK	Unapproved	—
JP	—	Unapproved
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Cagrilintide and Survodutide?: Cagrilintide is classified as "Metabolic", while Survodutide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Survodutide?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Survodutide in Germany and the United States?: Germany: Cagrilintide — Unapproved, Survodutide — Unapproved. United States: Cagrilintide — Unapproved, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Survodutide

Germany

Unapproved

—

Unapproved

United States

Unapproved

Frequently asked questions

What is the difference between Cagrilintide and Survodutide?

Cagrilintide is classified as "Metabolic", while Survodutide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Survodutide?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Survodutide in Germany and the United States?

Germany: Cagrilintide — Unapproved, Survodutide — Unapproved. United States: Cagrilintide — Unapproved, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.